Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis

Inclusion Criteria: * Symptoms of gastroparesis (e.g., nausea, early satiety, fullness, bloating, upper abdominal pain, retching or vomiting) for at least 3 months prior to Screening * Body Mass Index (BMI) between 18 and 35 kg/m2, inclusive * Gastroparesis Cardinal Symptom Index (GCSI-2W) composite score ≥2 and ≤4 at Screening * Delayed gastric emptying, defined as a gastric emptying half-time (GE t1/2) \> 160 minutes as determined by \[13C\]-octanoate breath test, at Screening * Upper gastrointestinal (UGI) obstruction ruled out by endoscopy or other imaging reasonably proximal to the diagnosis of gastroparesis Exclusion Criteria: * Acute severe gastroenteritis within 2 weeks prior to Screening * History of gastric outlet obstruction * Prior history of gastric surgery, including but not limited to gastrectomy, gastric bypass, gastric banding, pyloroplasty, vagotomy, or fundoplication * Recurrent vomiting, defined as vomiting more than 2 days per week * Hospitalization for treatment of gastroparesis or complications of diabetes within 4 weeks prior to Screening * Presence of thyroid dysfunction not controlled by treatment. Subjects with abnormal thyroid stimulating hormone (TSH), hypothyroidism, or hyperthyroidism at Screening * If Type 1 or Type 2 diabetic, a glycosylated hemoglobin (HbA1c) level \>10% or a glucose \> 250 mg/dL at Screening